A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer
This study will evaluate the safety, tolerability, and pharmacokinetics of BLYG8824A and will make a preliminary assessment of the anti-tumor activity of BLYG8824A in patients with locally advanced or metastatic colorectal cancer.
Colorectal Cancer
DRUG: BLYG8824A
Incidence and Nature of DLTs, Approximately 48 months|Number of Patricipants with Adverse Events, Approximately 48 months|Number Of Cycles Received, Approximately 48 months|Dose Intensity, Approximately 48 months|Maximum Tolerated Dose(s) MTD(s) of BLYG8824A, Approximately 48 months
Serum Concentration of BLYG8824A, At predifined interevals from Cycle 1 Day 1; Cycle 2 Day 1; Cycles ≥ 3, Day 1; Treatment Completion/ Discontinuation (Cycle length: 21 days)|Overall Response Rate (ORR), ORR is defined as the proportion of patients with a complete response (CR) or partial response (PR) as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), Approximately 48 months|Duration of Response (DOR), Duration of response (DOR), defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1, Approximately 48 months|Presence of Anti-drug Antibodies (ADAs), Cycle 1, Day 1; Cycle 2 Day 1; Cycles ≥ 3, Day 1; Treatment Completion/ Discontinuation (Cycle length: 21 days)
This study will evaluate the safety, tolerability, and pharmacokinetics of BLYG8824A and will make a preliminary assessment of the anti-tumor activity of BLYG8824A in patients with locally advanced or metastatic colorectal cancer.